All Type of News
Pharmaking to voluntarily withdraw from KPMA
Pharmaking, which arose public criticism through the CEO’s detention on suspicion of KRW 5 billion illegal rebate provision, has voluntarily withdrawn from the Korea Pharmaceutical Manufacturers Association.
The for...
Celltrion’s biosimilar ‘Remsima’ cruising European market
The world’s first biosimilar antibody developed by Celltrion, Remsima, has exceeded 70% in the European market share.
According to Celltrion, the Remsima’s market share growth rate in the last 1st quarter’s entire in...
“Too high insurance rates created National Insurance’s collective surplus of KRW 17 trillion”
Since collective surpluses of KRW 17 trillion were created in the National Health Insurance, the National Assembly Budget Office analyzed this as excessive insurance rates and ordered the Ministry of Health and Welfar...
What are doctors’ opinions over mortality risk issue of ‘Yasmin’?
When it came to recently-issued suspicion on the death related to the birth control pill, ‘Yasmin,’ domestic medical personnel advised it needs to be carefully approached.
They said since it is clinically useful as c...
Parecoxib concerning safety failed to come back again in 10 years
The Pfizer’s anti-inflammatory drug, ‘parecoxib(product name: dynastat),’ tried to enter the prescription market against its safety and efficacy issues again in 10 years, but finally failed.
The COX-2 inhibitor anti-...
Will multinational companies enter pharmaceutical bidding pool?
As soon as the Ministry of Health and Welfare decided a policy to exclude prices that were bid in the drug bidding pool for public and private hospitals from drug price cuts, multinational pharmaceutical companies hav...
Daiichi Sankyo’s takeover of ‘Effient’ licenseDaiichi Sankyo Korea(CEO Dae-joon Kim) announced a transfer of the product right of an oral antiplatelet agent, ‘Effient(generic name: prasugrel),’ from Lilly Korea as of the 13...
|
‘Communication’ between Swiss President and domestic pharmaceutical industry
The pharmaceutical industry will have a meeting with the President of the Swiss Confederation, Johann Schneider-Ammann.
According to the industry, President Johann Schneider-Ammann will exchange opinions about the he...
Clear opinion differences between Sanofi vs LG over ‘Zemiglo’
The outline of the lawsuit over ‘Zemiglo,’ an antidiabetic developed by LG Life Sciences, became visible.
The first defense for the damage suit filed by the previous seller of Zemiglo, Sanofi-Aventis Korea, against...
Potential domestic vaccines against multinational companies’ ones
Vaccine is one of the fields which have become energetic as a part of ‘prevention.’ As people started to give more importance towards ‘prevention’ than ‘treatment,’ development of vaccines have naturally been influenc...
